nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

07.02.2019 | case report

The path of an esophageal carcinoma patient from curative to palliative treatment

verfasst von: Ercan Müldür, MD, Karl Mayrhofer, Wolfgang Hilbe

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Summary

We hereby report the course and management of a patient with human epidermal growth factor receptor 2 negative esophageal cancer who received neoadjuvant chemoradiation, surgical resection and subsequently palliative therapy for recurrent disease. The critical role of the staging procedure is discussed. Additionally the options of systemic palliative therapies are presented and the rationale for immuno-oncologic treatment is highlighted. The patient received pembrolizumab as second-line therapy, which unfortunately did not result in a response and caused minor autoimmune side effects.

Vorheriger Artikel A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors

Nächster Artikel An update on immunotherapy in breast cancer

van Hagen P, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRef

Lewis I. The surgical treatment of carcinoma of the oesophagus with special reference to a new operation for growths of the middle third. Br J Surg. 1946;34(133):18–31.CrossRef

Al-Batran S‑E, et al. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO). Ann Oncol. 2017;28(suppl_3). https://doi.org/10.1093/annonc/mdx302.007 CrossRef

Fuchs CS, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. Jama Oncol. 2018;4(5):e180013.CrossRef

Nishino M, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373(3):288–90.CrossRef

Villadolid J, et al. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560–75.PubMedPubMedCentral

Li Z, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS ONE. 2018;13(1):e189294.

Rizvi FH, et al. Complete pathological response after neoadjuvant treatment in locally advanced esophageal cancer predicts long term survival: A retrospective cohorte study. Int J Surg. 2014;12(6):621–5.CrossRef

Donahue JM, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009;87(2):392–9.CrossRef

10.

You JJ, et al. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer. J Thorac Oncol. 2013;8(12):1563–9.CrossRef

11.

Meyers BF, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007;133(3):738–745.e1.CrossRef

12.

Young K, et al. Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Therap Adv Gastroenterol. 2015;8(6):373–83.CrossRef

13.

Shitara K, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.CrossRef

14.

Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.CrossRef

15.

Le DT, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol. 2016;34(4_suppl):195–195.CrossRef

Titel: The path of an esophageal carcinoma patient from curative to palliative treatment
verfasst von: Ercan Müldür, MD
Karl Mayrhofer
Wolfgang Hilbe
Publikationsdatum: 07.02.2019
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-0475-8

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Influencing factors on career choice and current occupation analysis of adult survivors of childhood cancer: a special focus on health-related occupations

Therapeutic endoscopic strategies in early esophageal cancer and dysplastic Barrett’s epithelium

Editorial: critical issues in lymphoma management

Demystification of palliative care. In regard to Masel and Kreye

Current lymphoma diagnostic standards: the pathologists’ view

ESMO 2018—personal highlights